Product Reports Resources Pricing Login Book a demo

Cytokinetics

Biotech & Life Sciences · South San Francisco, United States · Founded 1998 · IPO 2004

Cytokinetics | Muscle Biology Therapies | Home

Valuation $11B
Revenue $113M

Investors

4 investors on Cytokinetics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 3 investors entered at this stage
Sevin Rosen Funds
Vale Group
Duke University

Global footprint

Where Cytokinetics has talent and traffic

Workforce by country
🇺🇸 United States · South San Francisco HQ
Book a demo for the full country breakdown
Web traffic by country
100K monthly visits
across markets
🇺🇸 United States93%
🇨🇭 Switzerland3.1%
🇮🇳 India1.9%
🇬🇧 United Kingdom1.5%
🇨🇦 Canada1.2%
Top 5 markets shown

Talent graph

The shape of Cytokinetics's talent

Dealroom maps Cytokinetics's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

7 standout operatorsDealroom-flagged across the org
4 AI specialistsincl. 2 core researchers
785 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Cytokinetics's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$139M patent portfolio · 93 active families

Estimated portfolio value
$139M
1.3% of market cap · 1071× larger than top peer Akero Therapeutics ($130k)
93 active patent families
Where Cytokinetics innovates Acid amino sequencesAmino acidDiseaseDisease injuryNucleic acid

Where Cytokinetics concentrates vs peers

Each axis is a top-10 topic across Cytokinetics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

Cytokinetics's 4 investments and acquisitions.

Every disclosed deal where Cytokinetics appeared as a backer or acquirer, 2023–2025. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

4 deals across Cytokinetics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        02 · Portfolio market map

        Cytokinetics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        4 of 4 deals

        Market sentiment

        What the market is saying about Cytokinetics

        An AI-synthesized read of the highest-engagement posts about Cytokinetics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Cytokinetics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.